Abstract
A role for calponin (Cp) in mediating smooth muscle (SM) contraction

The basic isoform of Calponin (henceforth denoted as Cp) is an actin-binding protein present in both the cytoskeleton and contractile machinery of SM cells [1]. It has been shown also to be synthesized in endothelial cells (EC) [2-4]. Originally purified from chicken gizzard SM by Takahashi et al. [5], Cp was subsequently identified as a 34-kD protein, which bound to tropomyosin [6]. Because of its selective localization, Cp has been deemed a critical protein in the regulation of SM contraction. Mezgueldi et al. [7, 8] identified an actin-binding site. This site also contains the part of Cp that, by binding to actin, inhibits myosin ATPase activity. The mechanism by which Cp regulates SM contraction is somewhat controversial and may involve either direct inhibition of acto-myosin cross-bridging, Cp-specific signalling, or a combination of the two. In vitro work revealed that during SM's relaxed state, Cp is bound to acto-myosin, this binding inhibiting actomyosin cross-bridge formation [8, 9], thus ultimately preventing SM contraction. Worth et al. [10] demonstrated increased Cp protein expression in SM's contractile state. Two other in vitro works
showed that application of Cp in a dose-dependent fashion increase SM contraction [11, 12] . In contrast in whole muscle preparations, Cp appeared to have somewhat different effects. Jaworowski et al. [13] , using intact skinned SM from guinea pig, reported that while Cp inhibited maximal shortening velocity, it had only a minor influence on the force of contraction (~10% reduction). They further suggested that Cp may modulate the rate of acto-myosin cross-bridging. Similarly, Obara et al. [14] presented data supporting the concept that rather than directly inhibiting acto-myosin, Cp [18] [19] [20] . Given [26, 27] . Cp dephosphorylation via a Cp-specific phosphatase is thought to restore Cp-inhibition of acto-myosin cross bridging, thus returning SM to its relaxed state [28] . In addition only THR-184 was shown to significantly affect (i.e. enhance) vasoconstriction [29] . Based [17, 30, 31] . Again, this discrepancy could be the result of studying isolated SM cells versus intact muscle [17] . [46] , ischaemia/reperfusion [47] , hypertension [48] , subarachnoid haemorrhage [49, 50] , vasospasm [51, 52] [53] .
Cp localization and function in the brain
Cp and TBI
TBI results in a chronic state of enhanced vasoreactivity of reacting microvessels, which leads to hypoperfusion (decreased CBF)
and hypoxia of the brain parenchyma [53] [54] [55] [56] [57] [58] [59] , growth factors [60, 61] and neurochemicals [54, [62] [63] [64] (Fig. 2) . We then asked the question whether the observed molecular and functional changes correlated with alterations in cognitive behaviours, which are also known to occur after TBI. As such, our rodent model of diffuse TBI causes significant food acquisition and retention memory loses performed in an automated radial arm maze, with such deficits persisting up to 27 days after impact (Fig. 3) . Using the same behaviour paradigm, we found that ICV peptide administration improved performance in the radial arm maze compared to that of animals that only received vehicle injections (Fig. 3) . More recently, we are exploring the feasibility of using Cp gene therapy as a therapy for improving CBF and cognitive outcome following TBI. [72, 73] . Beginning in the early 1990s, clinical trials using ETrA/B antagonists were introduced for its potential role in ameliorating vasospasm in several pathologic states [74, 75] . Since then, ET-1 has been a target for improving blood flow to several organs in a number of pathologic states including hypertension [76] hepatorenal syndrome [77] , heart failure [78] and decreased cerebral blood flow and hypoxia [79] . In 1995, Luscher and Wenzel published one of the first reviews where ET-1 receptor antagonists were identified as therapeutic agents to treat vascular disorders in clinical settings [80] . In their 1999 review, Benigni and Remuzzi [81] [82, 83] . Specifically, we have reported that ET-1, ETrA and ETrB are up-regulated following TBI [84, 85] . Further, we have demonstrated that by blocking the ETrA receptor, we can block the hypoperfusion that follows brain injury [86] .
Endothelin (ET)-1, its receptors (ETrA, ETrB) and Cp-mediated vasoreactivity: therapeutic implications
Because our work and that of others support a pivotal role of ET-1 and its receptors ETrA and ETrB in the control of vascular tone in normal and injured brains, we have included here, a brief discussion on these substances. Likewise, the causal association between ET-1 receptor-mediated vasoreactivity and Cp-mediated SM contractility is also explained. ET-1 is a powerful vasoconstrictor, which exerts vasoactive actions through its two G-protein-coupled receptors, A and B [71]. Activation of either receptor is coupled with activation of PKC. However activation of ETrA results in vasoconstriction, whereas that of ETrB causes vasodilation
How Cp may be implicated in the signal transduction of ET-1 and its receptors in normal and injured brain was further demonstrated by us. As such, ETrA antagonism also blocked Cp phosphorylation and improved hypoperfusion and CBF after TBI [85]. In order to further establish a cause-effect relationship between Cp phosphorylation and ET-1 receptor signalling, we blocked PKC-induced phosphorylation of Cp by application of chelerythine. It is known that
ETrA is coupled to PKC signalling [72, 73] . Therefore, when we injected chelerythrine to block PKC prior to TBI, this intervention [70] . Taken together, we propose the following mechanism leading to vasoconstriction (Fig 4) 
resulted in a reduction both of Cp phosphorylation, as detected by 2-dimensional gel electrophoresis, and cerebral hypoperfusion (i.e. enhanced CBF) as detected by ASL-MRI after TBI
